New Three-Drug cocktail aims to outsmart tough leukemia
NCT ID NCT06644183
First seen Feb 17, 2026 · Last updated Jun 22, 2026 · Updated 15 times
Summary
This study tests a new combination of three drugs—roginolisib, venetoclax, and rituximab—in people with chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatments. The goal is to see if the combination is safe and can wipe out leukemia cells more effectively. About 64 participants will receive the drugs orally or by infusion, and researchers will measure how many achieve undetectable minimal residual disease in their bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Roginolisib (a targeted drug) combined with venetoclax and rituximab
What this could lead to
If successful, this combination could offer a more effective and tolerable treatment option for people with hard-to-treat CLL, potentially leading to longer remission without the need for continuous therapy.
What could go wrong
This is an early-phase trial with only 64 participants, so results may not apply to everyone. The drugs can cause side effects like liver issues, rash, diarrhea, and infections. The combination may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.